Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZD 1839 in Recurrent/Metastatic Head and Neck Cancer
NCT00015964Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Mar 2001
- Primary completion
- Sep 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by University of Chicago. Primary endpoint: Early response rates at 2 months. Started Mar 2001; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00015964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00015964.